Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ERAS-0015 + Panitumumab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ERAS-0015 | ERAS 0015|ERAS0015 | KRAS Inhibitor 30 | ERAS-0015 is a pan-KRAS molecular glue, which targets GTP-bound RAS and potentially decreases proliferation of tumor cells harboring mutations at KRAS G12, G13, and Q61 and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 390). | |
| Panitumumab | Vectibix | ABX-EGF | EGFR Antibody 73 | Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06983743 | Phase I | ERAS-0015 + Pembrolizumab ERAS-0015 + Panitumumab ERAS-0015 | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors (AURORAS-1) | Recruiting | USA | 0 |